Colorectal Cancer

A panel of oncologists shares comprehensive insight to clinical trial data with tucatinib in patients with HER2+ metastatic colorectal cancer.

Julien Taieb, MD, PhD, discusses the safety profile associated with trifluridine/tipiracil with bevacizumab in refractory metastatic colorectal cancer.

An expert on colorectal cancer discusses the relationship between HER2 status and treatment selection and response.

Tanios S. Bekaii-Saab, MD, gives an overview of the presentation trends and molecular testing practices for metastatic colorectal cancer.

Laith Abushahin, MD, discusses the evolution of targeted therapy for patients with metastatic colorectal cancer and the importance of biomarker testing in this patient population.

Leap Therapeutics has launched the randomized, controlled part B of the phase 2 DeFianCe trial, which will evaluate DKN-01 in combination with bevacizumab and chemotherapy as second-line therapy in patients with advanced colorectal cancer.

Switching their focus to HER2+ metastatic colorectal cancer, panelists discuss best practices in testing HER2 to aid in the timely selection of best available therapies.

Expert perspectives on novel combination and immunotherapy strategies within BRAF-mutated metastatic colorectal cancer management.

The combination of botensilimab and balstilimab elicited durable responses and provided overall survival benefits in patients with microsatellite stable metastatic colorectal cancer that is resistant to chemotherapy and/or immunotherapy.

Julien Taieb, MD, discusses the importance of combining fluoropyrimidines with bevacizumab, key findings from the SUNLIGHT trial and the post-hoc analysis, and how these results may shake up the colorectal cancer treatment paradigm.

Deb Schrag, MD, MPH, discusses findings from the phase 2/3 PROSPECT trial in patients with rectal cancer.

Shared insight to the importance of tumor sidedness and its impact on the selection of EGFR-targeted therapy in metastatic colorectal cancer.

Key opinion leaders in metastatic colorectal cancer management review data from the BREAKWATER study in BRAF-V600E–mutated disease.

Centering discussion on patients with BRAF-V600E mutations in metastatic colorectal cancer, panelists reflect on the treatment armamentarium in this setting.

A brief review of how circulating tumor DNA testing has impacted the real-world management of patients with metastatic colorectal cancer.

Kanwal P. S. Raghav, MBBS, MD, discusses the rationale behind the phase 2 DESTINY-CRC02 trial evaluating fam-trastuzumab deruxtecan-nxki in patients with metastatic colorectal cancer (mCRC) with HER2 amplification or overexpression.

A focused discussion on the respective roles of circulating tumor DNA and minimal residual disease testing in the management of patients with nonmetastatic colorectal cancer.

Expert panelists provide their perspective on the current state of molecular testing in metastatic colorectal cancer and how it impacts treatment pathways.

Julien Taieb, MD, PhD, discusses key findings from a post-hoc analysis of the phase 3 SUNLIGHT trial of combination of trifluridine/tipiracil with bevacizumab in patients with refractory metastatic colorectal cancer.

Kanwal Pratap Singh Raghav MBBS, MD, discusses data from DESTINY-CRC01 that supported the DESTINY-CRC02 trial, key efficacy and safety data from the trial, and the importance of identifying patients with HER2-positive CRC who may benefit from ADCs like T-DXd in clinical practice.

The European Medicines Agency has validated and accepted a marketing authorization application for priority review for fruquintinib for the treatment of adult patients with pretreated metastatic colorectal cancer.

Kathryn Hitchcock, MD, PhD, discusses the rationale for the ongoing phase 3 ERAsur trial investigating total ablative therapy in patients with limited metastatic colorectal cancer and details the methodologies being used in this study.

Isabelle Franklin discusses the effects of social determinants of health on rates of colorectal cancer screening.

The FDA has approved FoundationOne CDx for use as a companion diagnostic to determine patients with BRAF V600E–mutated metastatic colorectal cancer who may be candidates to receive encorafenib in combination with cetuximab.

In this sixth episode of OncChats: Understanding Lynch Syndrome and Cancer Risk, Fay Kastrinos, MD, MPH, shares future considerations for optimizing the identification of Lynch syndrome and other efforts underway to prevent colorectal cancer in those who have this condition.